Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CFSAN

This article was originally published in The Tan Sheet

Executive Summary

Twelve-year FDA veteran Susan Alpert, MD/PhD, assumes role of CFSAN Director for Food Safety, effective Oct. 25. Since 1993, Alpert has served as director of the Center for Devices & Radiological Health Office of Device Evaluation, overseeing the agency review of all medical devices. A pediatrician with a background in infectious diseases and microbiology, she previously worked as a supervisory medical officer in CDER. She succeeds Morris Potter, who is leaving CFSAN to become executive director of the International Life Sciences Institute and ILSI North America. In her new role, Alpert will report directly to CFSAN Director Joseph Levitt, who also came over from CDRH in February 1998 (1"The Tan Sheet" Jan. 19, 1998, p. 14)

You may also be interested in...



FDA names Joseph Levitt new CFSAN director; Fred Shank to ambassadorial role.

FDA NEW CFSAN DIRECTOR LEVITT HAS NLEA BACKGROUND to go with his center management experience as deputy director of FDA's Center for Devices & Radiological Health. Effective Feb. 2, Joseph Levitt will become the new director of the Center for Food Safety & Applied Nutrition, succeeding Fred Shank, PhD, who has served in that position for more than 10 years.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090402

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel